SCHEMBL15084392

SCHEMBL15084392

CC1CC(C(=O)O)CN(Cc2c(F)cccc2F)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 8/20 0.46
S1PR5 Q9H228 6/20 0.46
ALDH1A1 P00352 5/20 0.44
KDM4E B2RXH2 4/20 0.44
TSHR P16473 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
GRK5 P34947 1/20 0.42
CDK8 P49336 1/20 0.42
EED O75530 2/20 0.41
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 1/20 0.41
S1PR3 Q99500 2/20 0.41
S1PR4 O95977 1/20 0.41
POLB P06746 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
SIGMAR1 Q99720 1/20 0.40
DRD4 P21917 1/20 0.40
ALOX15 P16050 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15084388 0.89 CD274 (0.45) KDM4EL3MBTL1MEN1KMT2A
SCHEMBL15084389 0.86 ALDH1A1 (0.46) ALDH1A1KDM4ETSHRTDP1L3MBTL1
SCHEMBL807604 0.85 ALDH1A1 (0.50) S1PR1S1PR5ALDH1A1KDM4ETDP1
SCHEMBL10212863 0.85 S1PR5 (0.47) S1PR1S1PR5ALDH1A1KDM4ETSHR
SCHEMBL18360682 0.84 ALDH1A1 (0.45) S1PR1S1PR5ALDH1A1KDM4ETSHR
SCHEMBL15084365 0.84 HRH3 (0.51) ALDH1A1KDM4ETSHREEDPOLB
SCHEMBL15084376 0.78 L3MBTL1 (0.44) ALDH1A1KDM4ETSHRTDP1L3MBTL1
SCHEMBL15084390 0.78 EED (0.43) ALDH1A1KDM4ETSHREEDMEN1
SCHEMBL18360692 0.77 CYP2A13 (0.56) ALDH1A1KDM4ETSHRTDP1L3MBTL1
SCHEMBL15084355 0.77 EED (0.56) EED

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242981-B2 Fused pyrazole derivatives as novel ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2016-01-26 US disclosed
US-20130172341-A1 FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS MERCK SHARP & DOHME LLC 2013-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172341-A1 FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS MAPK1, MAPK3, MAP3K1 S1PR1 1937/4885S1PR5 2678/4885ALDH1A1 781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.